<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153051">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01925690</url>
  </required_header>
  <id_info>
    <org_study_id>0033769</org_study_id>
    <secondary_id>National MS Society</secondary_id>
    <nct_id>NCT01925690</nct_id>
  </id_info>
  <brief_title>Development of a Motivational Intervention to Improve Treatment Adherence in MS</brief_title>
  <acronym>MIMS</acronym>
  <official_title>Development of a Motivational Intervention to Improve Treatment Adherence in MS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri, Kansas City</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Multiple Sclerosis Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Missouri, Kansas City</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As many as 50% of MS patients prematurely discontinue their disease modifying medications.
      For this study, we will develop a telephone-based talk therapy intervention and then conduct
      a randomized controlled trial.  Patients will be assigned to either 5 weekly 20 minute
      telephone sessions of psychotherapy or a brief education control condition. We hypothesize
      that patients undergoing phone therapy will be more likely to indicate they are interested
      in resuming taking disease modifying medications than patients given brief education and
      treatment as usual.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>Adherence Treatment Survey</measure>
    <time_frame>10 weeks after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Whether the patient indicates if he/she decided to re-initiate disease modifying therapies on a &quot;yes&quot;/&quot;no&quot; question.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence Treatment Survey</measure>
    <time_frame>10 weeks after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Whether the patient reports that he/she plans to discuss disease modifying therapies with a care provider on a &quot;yes&quot;/&quot;no&quot; question.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence Treatment Survey</measure>
    <time_frame>5 weeks after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Whether the patient reports that he/she plans to discuss disease modifying therapies with a care provider on a &quot;yes&quot;/&quot;no&quot; question.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence Treatment Survey</measure>
    <time_frame>5 weeks after enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Whether the patient indicates if he/she decided to re-initiate disease modifying therapies on a &quot;yes&quot;/&quot;no&quot; question.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Motivation/Readiness Qustionnaire</measure>
    <time_frame>10 weeks post-enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Whether there is increased self-reported motivation to take disease modifying therapies on a 1-10 likert-type scale.</description>
  </other_outcome>
  <other_outcome>
    <measure>Motivation/Readiness Questionnaire</measure>
    <time_frame>5 weeks post-enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Whether there is an increase in self-reported motivation to take disease modifying therapies on a 1-10 likert-type scale.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Relapsing-remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Brief Education</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive a brief educational packet along with treatment as usual</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MI-CBT Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive five 20 minute phone sessions of motivational interviewing/cognitive behavioral therapy weekly along with a brief educational packet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Motivational Interviewing-Cognitive Behavioral Therapy (MI-CBT)</intervention_name>
    <description>A telephone based talk therapy discussing pros and cons of medication use in MS.</description>
    <arm_group_label>MI-CBT Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Brief Education</intervention_name>
    <description>Give patients a pamphlet discussing pros and cons of disease modifying therapies</description>
    <arm_group_label>Brief Education</arm_group_label>
    <arm_group_label>MI-CBT Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of relapsing remitting MS based on established guidelines

          -  Previously discontinued recommended therapy

          -  Provider recommendation for DMT re-initiation

          -  At least 18 years of age

          -  Access to a telephone

          -  English speaking
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jared M Bruce, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri, Kansas City</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jared Bruce, PhD</last_name>
    <phone>816-235-5429</phone>
    <email>brucejm@umkc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Missouri-Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Dreyfus, Ph.D.</last_name>
      <phone>816-235-6302</phone>
    </contact>
    <investigator>
      <last_name>Jared Bruce, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kessler Rehabillitation Institute</name>
      <address>
        <city>West Orange</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Strober, PhD</last_name>
      <email>lstrober@kesslerfoundation.org</email>
    </contact>
    <investigator>
      <last_name>Lauren Strober</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://sites.google.com/site/clinicalneuropsychologylab/contact-us</url>
    <description>Clinical Neuropsychology Lab Research</description>
  </link>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 19, 2013</lastchanged_date>
  <firstreceived_date>August 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri, Kansas City</investigator_affiliation>
    <investigator_full_name>Jared Bruce</investigator_full_name>
    <investigator_title>Associate Professor of Psychology</investigator_title>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Disease modifying medication</keyword>
  <keyword>Relapsing-Remitting MS</keyword>
  <keyword>Motivational Interviewing</keyword>
  <keyword>Telephone Counseling</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
